JP2008247828A - Aqueous medicine composition containing latanoprost - Google Patents

Aqueous medicine composition containing latanoprost Download PDF

Info

Publication number
JP2008247828A
JP2008247828A JP2007091875A JP2007091875A JP2008247828A JP 2008247828 A JP2008247828 A JP 2008247828A JP 2007091875 A JP2007091875 A JP 2007091875A JP 2007091875 A JP2007091875 A JP 2007091875A JP 2008247828 A JP2008247828 A JP 2008247828A
Authority
JP
Japan
Prior art keywords
aqueous pharmaceutical
latanoprost
pharmaceutical composition
present
medicine composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007091875A
Other languages
Japanese (ja)
Inventor
Kohei Yoda
耕平 依田
Emi Kawaguchi
恵美 川口
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wakamoto Pharmaceutical Co Ltd
Original Assignee
Wakamoto Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wakamoto Pharmaceutical Co Ltd filed Critical Wakamoto Pharmaceutical Co Ltd
Priority to JP2007091875A priority Critical patent/JP2008247828A/en
Publication of JP2008247828A publication Critical patent/JP2008247828A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide a latanoprost containing aqueous medicine composition in which the existing of an insoluble foreign body is controlled in an aqueous medicine composition containing latanoprost and a preservative, and to provide a method of controlling the existing of a foreign body. <P>SOLUTION: The aqueous medicine composition in which the existing of an insoluble foreign body is controlled notably comprises compounding edetic acid or its salt permitted pharmacologically in an aqueous medicine composition containing latanoprost and a preservative. Moreover, the method to control the existing of a foreign body comprises further adding edetic acid or its salt permitted pharmacologically in an aqueous solution which is an aqueous medicine composition filled up into a resin container and contains latanoprost and a preservative. <P>COPYRIGHT: (C)2009,JPO&INPIT

Description

本発明は、ラタノプロストを有効成分とし、エチレンジアミン四酢酸または薬学的に許容されるその塩を配合することにより、異物の出現が抑制された水性医薬組成物に関するものである。 The present invention relates to an aqueous pharmaceutical composition containing latanoprost as an active ingredient and containing ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof to suppress the appearance of foreign substances.

点眼剤などの水性医薬組成物では、白色光源下においてたやすく検出される不溶性異物がないことが必須の要件となっている。これは日本薬局方の製剤総則にて述べられている。 In aqueous pharmaceutical compositions such as eye drops, it is an essential requirement that there be no insoluble foreign matter that is easily detected under a white light source. This is described in the Japanese Pharmacopoeia General Rules for Preparations.

不溶性異物として認められるものとしては結晶性の異物や粉末状の異物などが挙げられる。不溶性異物が出現する原因としては物質同士の配合変化による析出、熱等のエネルギーによる新規物質の発生、溶液温度の変化による溶解度の変化などが挙げられる。 Examples of the insoluble foreign matter include crystalline foreign matter and powdery foreign matter. The causes of the appearance of insoluble foreign substances include precipitation due to mixing changes between substances, generation of new substances due to energy such as heat, and changes in solubility due to changes in solution temperature.

一方、点眼剤などの水性医薬組成物には、一般的に緩衝剤、等張化剤、pH調節剤、保存剤、可溶化剤、安定化剤等を加えることができる。 On the other hand, buffers, isotonic agents, pH adjusters, preservatives, solubilizers, stabilizers and the like can generally be added to aqueous pharmaceutical compositions such as eye drops.

不溶性異物の出現を抑制する手段として可溶化剤を用いることがある。これは可溶化効果により不溶性異物の出現を抑えることによると考えられる。 A solubilizer may be used as a means for suppressing the appearance of insoluble foreign matter. This is thought to be due to the suppression of the appearance of insoluble foreign matter due to the solubilization effect.

安定化剤はある物質が分解等により新規物質が出現し、その物質が不溶性異物として出現する場合、分解を抑制することにより、結果的に不溶性異物の出現を抑制することができる。しかし、これは分解を抑制することができる安定化剤が見出された場合に限る。
水性液剤において、安定化剤としてエチレンジアミン四酢酸の使用が報告されている（特許文献1）。しかし、溶解する薬物はベンゾピラン誘導体であり、本発明のラタノプロストとまったく構造が異なっている。また、プロスタグランジンの分解抑制のために抗酸化剤として、エチレンジアミン四酢酸二ナトリウムが使用されている（特許文献2）。しかし、その抗酸化剤の使用目的は、点眼液中でのプロスタグランジン誘導体の分解を抑制することであって、異物の出現を抑制することではない。ベンズオキサジン誘導体の点眼剤において、その不溶性異物の発生防止にキレート剤として、エチレンジアミン四酢酸二ナトリウムの添加が報告されている（特許文献3）。しかし、溶解する薬物は、本発明のラタノプロストとまったく構造が異なっている。
特開平5-213757 特開2002-161037 特開平11-92368 When a new substance appears due to decomposition or the like of a certain substance and the substance appears as an insoluble foreign substance, the stabilizer can be suppressed as a result by suppressing the decomposition. However, this is only the case when a stabilizer that can suppress degradation is found.
In aqueous liquid preparations, use of ethylenediaminetetraacetic acid as a stabilizer has been reported (Patent Document 1). However, the drug to be dissolved is a benzopyran derivative, which is completely different in structure from the latanoprost of the present invention. In addition, disodium ethylenediaminetetraacetate is used as an antioxidant to suppress prostaglandin degradation (Patent Document 2). However, the purpose of using the antioxidant is to suppress the degradation of the prostaglandin derivative in the eye drop, not to suppress the appearance of foreign substances. In the eye drops of benzoxazine derivatives, addition of disodium ethylenediaminetetraacetate has been reported as a chelating agent for preventing the generation of insoluble foreign substances (Patent Document 3). However, the drug to be dissolved is completely different in structure from the latanoprost of the present invention.
JP 5-213757 JP2002-161037 JP-A-11-92368

本発明の解決しようとする課題は、不溶性異物の出現が抑制されたラタノプロスト含有水性医薬組成物を提供することにある。 The problem to be solved by the present invention is to provide an aqueous pharmaceutical composition containing latanoprost in which the appearance of insoluble foreign matter is suppressed.

本発明者らは、水性医薬組成物の添加物が不溶性異物の出現に及ぼす影響について鋭意研究を行った。その結果、エチレンジアミン四酢酸または薬学的に許容されるその塩を配合することにより、不溶性異物の出現が顕著に抑制されることを見出し、本発明を完成した。 The inventors of the present invention conducted intensive studies on the influence of the aqueous pharmaceutical composition additive on the appearance of insoluble foreign matter. As a result, it has been found that by adding ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof, the appearance of insoluble foreign matter is remarkably suppressed, and the present invention has been completed.

本発明の水性医薬組成物はラタノプロスト、保存剤からなる水性医薬組成物の不溶性異物の出現を抑制できるという効果を有する。 The aqueous pharmaceutical composition of the present invention has the effect of suppressing the appearance of insoluble foreign matter in an aqueous pharmaceutical composition comprising latanoprost and a preservative.

本発明に用いられるラタノプロストの配合量は、期待される薬効が得られる濃度であれば特に制限はないが、好ましくは0.0005〜0.5w/v%であり、より好ましくは0.001〜0.01w/v%である。 The blending amount of latanoprost used in the present invention is not particularly limited as long as the expected medicinal effect is obtained, but is preferably 0.0005 to 0.5 w / v%, more preferably 0.001 to 0.01 w / v%. It is.

本発明に用いられるエチレンジアミン四酢酸または薬学的に許容されるその塩は、本発明の効果が得られれば特に制限はないが、例えば、ナトリウム塩、カリウム塩、カルシウム塩などを挙げることができる。この中でも、ナトリウム塩は水性医薬組成物に十分な不溶性異物の抑制効果が得られるので好ましい。 The ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof used in the present invention is not particularly limited as long as the effects of the present invention can be obtained, and examples thereof include a sodium salt, a potassium salt, and a calcium salt. Among these, a sodium salt is preferable because an inhibitory effect on insoluble foreign matters sufficient for an aqueous pharmaceutical composition can be obtained.

本発明に用いられるエチレンジアミン四酢酸または薬学的に許容されるその塩の使用濃度範囲は、本発明の効果が得られれば特に制限はないが、好ましくは0.0005〜10w/v%であり、より好ましくは0.001〜1w/v%である。 The concentration range of ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof used in the present invention is not particularly limited as long as the effect of the present invention is obtained, but is preferably 0.0005 to 10 w / v%, more preferably. Is 0.001-1 w / v%.

本発明に用いられる樹脂製容器の材質は、本発明の効果が得られれば特に制限はないが、好ましくはポリプロピレン、ポリエチレン、またはポリエチレンテレフタレートであり、より好ましくはポリプロピレンである。 The material of the resin container used in the present invention is not particularly limited as long as the effect of the present invention can be obtained, but is preferably polypropylene, polyethylene, or polyethylene terephthalate, and more preferably polypropylene.

本発明に用いられる保存剤は、塩化ベンザルコニウム、または塩化ベンゼトニウムであり、より好ましくは塩化ベンザルコニウムである。本発明における保存剤の使用濃度範囲は、本発明の効果が得られれば特に制限はないが、好ましくは0.0001〜0.1w/v%であり、より好ましくは0.001〜0.05w/v%である。 The preservative used in the present invention is benzalkonium chloride or benzethonium chloride, more preferably benzalkonium chloride. The concentration range of the preservative used in the present invention is not particularly limited as long as the effect of the present invention is obtained, but is preferably 0.0001 to 0.1 w / v%, more preferably 0.001 to 0.05 w / v%.

本発明における水性医薬組成物のpHは、本発明の効果が得られれば特に制限はないが、好ましくは4〜10であり、眼部に対する刺激性を考慮すると、好ましくは5.0〜8.0であり、特に好ましくは6.2〜7.2である。 The pH of the aqueous pharmaceutical composition in the present invention is not particularly limited as long as the effects of the present invention are obtained, but is preferably 4 to 10, and preferably 5.0 to 8.0 in consideration of irritation to the eye. Particularly preferred is 6.2 to 7.2.

本発明における水性医薬組成物の浸透圧比は、本発明の効果が得られれば特に制限はないが、好ましくは0.1〜4.0であり、眼部に対する刺激性を考慮すると、好ましくは0.5〜2.0であり、特に好ましくは0.8〜1.2である。 The osmotic pressure ratio of the aqueous pharmaceutical composition in the present invention is not particularly limited as long as the effect of the present invention is obtained, but is preferably 0.1 to 4.0, and preferably 0.5 to 2.0 in consideration of irritation to the eye. Particularly preferred is 0.8 to 1.2.

〔比較例1〜3及び実施例1〜3〕
滅菌精製水50mLに塩化ベンザルコニウム0.02 gを加え、溶解した。これにラタノプロスト0.005 gを加えた。溶液全体が澄明になったことを確認後、滅菌精製水で全容量100 mLとした。これをポリプロピレン、ポリエチレン、またはポリエチレンテレフタレート製容器に移して密閉し、本発明の水性医薬組成物 (比較例1〜3) を調製した。 [Comparative Examples 1-3 and Examples 1-3]
To 50 mL of sterilized purified water, 0.02 g of benzalkonium chloride was added and dissolved. To this was added 0.005 g of latanoprost. After confirming that the entire solution was clear, the total volume was adjusted to 100 mL with sterilized purified water. This was transferred to a container made of polypropylene, polyethylene, or polyethylene terephthalate and sealed to prepare aqueous pharmaceutical compositions (Comparative Examples 1 to 3) of the present invention.

滅菌精製水50mLに塩化ベンザルコニウム0.02 gを加え、溶解した。これにラタノプロスト0.005 gを加えた。さらに、エチレンジアミン四酢酸ナトリウム0.01 gを加えた。溶液全体が澄明になったことを確認後、滅菌精製水で全容量100 mLとした。これをポリプロピレン、ポリエチレン、またはポリエチレンテレフタレート製容器に移して密閉し、本発明の水性医薬組成物 (実施例1〜3) を調製した。 To 50 mL of sterilized purified water, 0.02 g of benzalkonium chloride was added and dissolved. To this was added 0.005 g of latanoprost. Further, 0.01 g of sodium ethylenediaminetetraacetate was added. After confirming that the entire solution was clear, the total volume was adjusted to 100 mL with sterilized purified water. This was transferred to a container made of polypropylene, polyethylene or polyethylene terephthalate and sealed to prepare aqueous pharmaceutical compositions (Examples 1 to 3) of the present invention.

〔試験例1〕
上記の比較例及び実施例で調製した水性医薬組成物を保存し、不溶性異物の有無を評価した。評価方法は白色光源下にて観察して不溶性異物を認めたものを「不溶性異物あり」とした。複数本数について観察して観察本数に対する不溶性異物ありの本数の割合をパーセントにて算出した。結果を表1に示す。 [Test Example 1]
The aqueous pharmaceutical compositions prepared in the above Comparative Examples and Examples were stored and evaluated for the presence or absence of insoluble foreign matter. As an evaluation method, an insoluble foreign matter was observed when observed under a white light source, and “insoluble foreign matter was present” was determined. By observing a plurality of the numbers, the ratio of the number of insoluble foreign matters to the number of observations was calculated as a percentage. The results are shown in Table 1.

Figure 2008247828
※PP：ポリプロピレン、PE：ポリエチレン、PET：ポリエチレンテレフタレート
Figure 2008247828
 * PP: Polypropylene, PE: Polyethylene, PET: Polyethylene terephthalate

比較例1〜3と実施例1〜3を比較した場合、エチレンジアミン四酢酸ナトリウムを添加することにより、不溶性異物の出現が60%以上抑制され、場合によっては全く出現しなくなることが示された。また、これにより本発明の効果は樹脂製容器の材質にかかわらず得られることが明らかとなった。 When Comparative Examples 1 to 3 and Examples 1 to 3 were compared, it was shown that the addition of sodium ethylenediaminetetraacetate suppressed the appearance of insoluble foreign matter by 60% or more, and in some cases it did not appear at all. Further, it has become clear that the effects of the present invention can be obtained regardless of the material of the resin container.

〔比較例4及び実施例4〜6〕
滅菌精製水50mLに塩化ベンザルコニウム0.02 gを加え、溶解した。これにラタノプロスト0.005 gを加えた。溶液全体が澄明になったことを確認後、滅菌精製水で全容量100 mLとした。これをポリプロピレン製容器に移して密閉し、本発明の水性医薬組成物 (比較例4) を調製した。 [Comparative Example 4 and Examples 4 to 6]
To 50 mL of sterilized purified water, 0.02 g of benzalkonium chloride was added and dissolved. To this was added 0.005 g of latanoprost. After confirming that the entire solution was clear, the total volume was adjusted to 100 mL with sterilized purified water. This was transferred to a polypropylene container and sealed to prepare an aqueous pharmaceutical composition of the present invention (Comparative Example 4).

滅菌精製水50mLに塩化ベンザルコニウム0.02 gを加え、溶解した。これにラタノプロスト0.005 gを加えた。さらに、リン酸二水素ナトリウム，リン酸水素二ナトリウム・12水和物をそれぞれ加え、エチレンジアミン四酢酸ナトリウム0.01 gを加えた。溶液全体が澄明になったことを確認後、滅菌精製水で全容量100 mLとした。これをポリプロピレン製容器に移して密閉し、本発明の水性医薬組成物 (実施例4〜5) を調製した。 To 50 mL of sterilized purified water, 0.02 g of benzalkonium chloride was added and dissolved. To this was added 0.005 g of latanoprost. Further, sodium dihydrogen phosphate and disodium hydrogen phosphate.12 hydrate were added, respectively, and 0.01 g of sodium ethylenediaminetetraacetate was added. After confirming that the entire solution was clear, the total volume was adjusted to 100 mL with sterilized purified water. This was transferred to a polypropylene container and sealed to prepare aqueous pharmaceutical compositions (Examples 4 to 5) of the present invention.

滅菌精製水50mLに塩化ベンザルコニウム0.02 gを加え、溶解した。これにラタノプロスト0.005 gを加えた。さらに、ホウ酸，ホウ砂をそれぞれ加え，エチレンジアミン四酢酸ナトリウム0.01 gを加えた。溶液全体が澄明になったことを確認後、滅菌精製水で全容量100 mLとした。これをポリプロピレン製容器に移して密閉し、本発明の水性医薬組成物 (実施例6) を調製した。 To 50 mL of sterilized purified water, 0.02 g of benzalkonium chloride was added and dissolved. To this was added 0.005 g of latanoprost. Furthermore, boric acid and borax were added, and 0.01 g of sodium ethylenediaminetetraacetate was added. After confirming that the entire solution was clear, the total volume was adjusted to 100 mL with sterilized purified water. This was transferred to a polypropylene container and sealed to prepare an aqueous pharmaceutical composition (Example 6) of the present invention.

〔試験例2〕
試験例1と同様な方法を用いて、比較例4及び実施例4〜6の不溶性異物を評価した。結果を表2に示す。 [Test Example 2]
Using the same method as in Test Example 1, insoluble foreign substances in Comparative Example 4 and Examples 4 to 6 were evaluated. The results are shown in Table 2.

Figure 2008247828
※PP：ポリプロピレン
Figure 2008247828
 * PP: Polypropylene

比較例4と実施例4〜6を比較した場合、エチレンジアミン四酢酸ナトリウムを添加することにより、不溶性異物の出現が60%以上抑制され、場合によっては全く出現しなくなることが示された。これにより、本発明の効果は緩衝剤の種類、または濃度に依存しないことが明らかとなった。 When Comparative Example 4 and Examples 4 to 6 were compared, it was shown that the addition of sodium ethylenediaminetetraacetate suppressed the appearance of insoluble foreign matter by 60% or more, and in some cases it did not appear at all. Thereby, it became clear that the effect of this invention is not dependent on the kind or density | concentration of a buffering agent.

〔比較例5及び実施例7〜9〕
滅菌精製水50mLに塩化ベンザルコニウム0.02 gを加え、溶解した。これにラタノプロスト0.005 gを加えた。溶液全体が澄明になったことを確認後、滅菌精製水で全容量100 mLとした。これをポリプロピレン製容器に移して密閉し、本発明の水性医薬組成物 (比較例5) を調製した。 [Comparative Example 5 and Examples 7-9]
To 50 mL of sterilized purified water, 0.02 g of benzalkonium chloride was added and dissolved. To this was added 0.005 g of latanoprost. After confirming that the entire solution was clear, the total volume was adjusted to 100 mL with sterilized purified water. This was transferred to a polypropylene container and sealed to prepare an aqueous pharmaceutical composition of the present invention (Comparative Example 5).

滅菌精製水50mLに塩化ベンザルコニウム0.02 gを加え、溶解した。これにラタノプロスト0.005 gを加えた。さらに、リン酸二水素ナトリウム，リン酸水素二ナトリウム・12水和物をそれぞれ加え、エチレンジアミン四酢酸ナトリウム0.001、0.01、または0.1 gを加えた。溶液全体が澄明になったことを確認後、滅菌精製水で全容量100 mLとした。これをポリプロピレン製容器に移して密閉し、本発明の水性医薬組成物 (実施例7〜9) を調製した。 To 50 mL of sterilized purified water, 0.02 g of benzalkonium chloride was added and dissolved. To this was added 0.005 g of latanoprost. Further, sodium dihydrogen phosphate and disodium hydrogen phosphate / dehydrate were added, respectively, and sodium ethylenediaminetetraacetate 0.001, 0.01, or 0.1 g was added. After confirming that the entire solution was clear, the total volume was adjusted to 100 mL with sterilized purified water. This was transferred to a polypropylene container and sealed to prepare aqueous pharmaceutical compositions (Examples 7 to 9) of the present invention.

〔試験例3〕
試験例1と同様な方法を用いて、比較例5及び実施例7〜9の不溶性異物を評価した。結果を表3に示す。 [Test Example 3]
Using the same method as in Test Example 1, the insoluble foreign substances in Comparative Example 5 and Examples 7 to 9 were evaluated. The results are shown in Table 3.

Figure 2008247828
※PP：ポリプロピレン
Figure 2008247828
 * PP: Polypropylene

比較例5と実施例7〜9を比較した場合、エチレンジアミン四酢酸ナトリウムを添加することにより、不溶性異物の出現が60%以上抑制され、場合によっては全く出現しなくなることが示された。これにより、本発明の効果はエチレンジアミン四酢酸ナトリウムの濃度にかかわらず得られることが明らかとなった。 When Comparative Example 5 was compared with Examples 7 to 9, it was shown that the addition of sodium ethylenediaminetetraacetate suppressed the appearance of insoluble foreign matter by 60% or more, and in some cases it did not appear at all. Thereby, it became clear that the effect of the present invention can be obtained regardless of the concentration of sodium ethylenediaminetetraacetate.

〔比較例6及び実施例10〕
滅菌精製水50mLに塩化ベンゼトニウム0.01 gを加え、溶解した。これにラタノプロスト0.005 gを加えた。溶液全体が澄明になったことを確認後、滅菌精製水で全容量100 mLとした。これをポリプロピレン製容器に移して密閉し、本発明の水性医薬組成物 (比較例6) を調製した。 (Comparative Example 6 and Example 10)
To 50 mL of sterilized purified water, 0.01 g of benzethonium chloride was added and dissolved. To this was added 0.005 g of latanoprost. After confirming that the entire solution was clear, the total volume was adjusted to 100 mL with sterilized purified water. This was transferred to a polypropylene container and sealed to prepare an aqueous pharmaceutical composition of the present invention (Comparative Example 6).

滅菌精製水50mLに塩化ベンゼトニウム0.01 gを加え、溶解した。これにラタノプロスト0.005 gを加えた。さらに、エチレンジアミン四酢酸ナトリウム0.01 gを加えた。溶液全体が澄明になったことを確認後、滅菌精製水で全容量100 mLとした。これをポリプロピレン製容器に移して密閉し、本発明の水性医薬組成物 (実施例10) を調製した。 To 50 mL of sterilized purified water, 0.01 g of benzethonium chloride was added and dissolved. To this was added 0.005 g of latanoprost. Further, 0.01 g of sodium ethylenediaminetetraacetate was added. After confirming that the entire solution was clear, the total volume was adjusted to 100 mL with sterilized purified water. This was transferred to a polypropylene container and sealed to prepare an aqueous pharmaceutical composition (Example 10) of the present invention.

〔試験例4〕
試験例1と同様な方法を用いて、比較例6及び実施例10の不溶性異物を評価した。結果を表4に示す。 (Test Example 4)
Using the same method as in Test Example 1, insoluble foreign substances in Comparative Example 6 and Example 10 were evaluated. The results are shown in Table 4.

Figure 2008247828
※PP：ポリプロピレン
Figure 2008247828
 * PP: Polypropylene

比較例6と実施例10を比較した場合、エチレンジアミン四酢酸ナトリウムを添加することにより、不溶性異物の出現が50%抑制された。これにより、本発明の効果は塩化ベンザルコニウム以外の保存剤についても得られることが明らかとなった。 When comparing Comparative Example 6 and Example 10, the addition of sodium ethylenediaminetetraacetate suppressed the appearance of insoluble foreign matter by 50%. Thereby, it became clear that the effect of this invention is acquired also about preservatives other than benzalkonium chloride.

Claims (7)

ラタノプロスト、保存剤、及び、エチレンジアミン四酢酸又はその薬学的に許容される塩、を含有する水性医薬組成物。 An aqueous pharmaceutical composition comprising latanoprost, a preservative, and ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof. 樹脂性容器に充填された請求項1に記載の水性医薬組成物。 2. The aqueous pharmaceutical composition according to claim 1, which is filled in a resinous container. エチレンジアミン四酢酸の薬学的に許容される塩がナトリウムである請求項1又は2に記載の水性医薬組成物。 The aqueous pharmaceutical composition according to claim 1 or 2, wherein the pharmaceutically acceptable salt of ethylenediaminetetraacetic acid is sodium. 樹脂性容器の材質がポリプロピレン、ポリエチレン、又は、ポリエチレンテレフタレートである請求項2又は3に記載の水性医薬組成物。 4. The aqueous pharmaceutical composition according to claim 2, wherein the resin container is made of polypropylene, polyethylene, or polyethylene terephthalate. 保存剤が4級アンモニウム塩化合物である、請求項１から４に記載の水性医薬組成物。 The aqueous pharmaceutical composition according to claims 1 to 4, wherein the preservative is a quaternary ammonium salt compound. 4級アンモニウム塩化合物が塩化ベンザルコニウム、又は、塩化ベンゼトニウム、である請求項5に記載の水性医薬組成物。 6. The aqueous pharmaceutical composition according to claim 5, wherein the quaternary ammonium salt compound is benzalkonium chloride or benzethonium chloride. 樹脂性容器に充填してなる水性医薬組成物であって、ラタノプロスト、及び、保存剤を含有する水溶液に、さらにエチレンジアミン四酢酸又はその薬学的に許容される塩を添加することによって異物の出現を抑制する方法。 An aqueous pharmaceutical composition filled in a resinous container, wherein ethylenediaminetetraacetic acid or a pharmaceutically acceptable salt thereof is further added to an aqueous solution containing latanoprost and a preservative to prevent the appearance of foreign substances. How to suppress.
JP2007091875A 2007-03-30 2007-03-30 Aqueous medicine composition containing latanoprost Pending JP2008247828A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2007091875A JP2008247828A (en) 2007-03-30 2007-03-30 Aqueous medicine composition containing latanoprost

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007091875A JP2008247828A (en) 2007-03-30 2007-03-30 Aqueous medicine composition containing latanoprost

Publications (1)

Publication Number Publication Date
JP2008247828A true JP2008247828A (en) 2008-10-16

Family

ID=39973209

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007091875A Pending JP2008247828A (en) 2007-03-30 2007-03-30 Aqueous medicine composition containing latanoprost

Country Status (1)

Country Link
JP (1) JP2008247828A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071113B2 (en) 2012-03-26 2018-09-11 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010570A1 (en) * 1998-08-21 2000-03-02 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations
JP2002161037A (en) * 2000-09-13 2002-06-04 Santen Pharmaceut Co Ltd Eye drop solution
JP2004123729A (en) * 2002-09-09 2004-04-22 Santen Pharmaceut Co Ltd Clear eye lotion containing latanoprost as effective ingredient
JP2005263792A (en) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd Clear latanoprost eye lotion
JP2006503913A (en) * 2002-10-24 2006-02-02 スキャンポ・アーゲー・（ユーエスエイ）・インク Methods and latanoprost-containing compositions for the treatment of ocular hypertension and glaucoma
JP2006169193A (en) * 2004-12-17 2006-06-29 Rohto Pharmaceut Co Ltd Tranilast-containing aqueous preparation
JP2006187602A (en) * 2004-12-09 2006-07-20 Santen Pharmaceut Co Ltd Product containing prostaglandin having fluorine atom in molecule
WO2006078659A2 (en) * 2005-01-20 2006-07-27 Breath Limited Stable prostaglandin-containing compositions

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000010570A1 (en) * 1998-08-21 2000-03-02 Senju Pharmaceutical Co., Ltd. Aqueous liquid preparations
JP2002161037A (en) * 2000-09-13 2002-06-04 Santen Pharmaceut Co Ltd Eye drop solution
JP2004123729A (en) * 2002-09-09 2004-04-22 Santen Pharmaceut Co Ltd Clear eye lotion containing latanoprost as effective ingredient
JP2006503913A (en) * 2002-10-24 2006-02-02 スキャンポ・アーゲー・（ユーエスエイ）・インク Methods and latanoprost-containing compositions for the treatment of ocular hypertension and glaucoma
JP2005263792A (en) * 2004-02-19 2005-09-29 Santen Pharmaceut Co Ltd Clear latanoprost eye lotion
JP2006187602A (en) * 2004-12-09 2006-07-20 Santen Pharmaceut Co Ltd Product containing prostaglandin having fluorine atom in molecule
JP2006169193A (en) * 2004-12-17 2006-06-29 Rohto Pharmaceut Co Ltd Tranilast-containing aqueous preparation
WO2006078659A2 (en) * 2005-01-20 2006-07-27 Breath Limited Stable prostaglandin-containing compositions

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10071113B2 (en) 2012-03-26 2018-09-11 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
US10632139B2 (en) 2012-03-26 2020-04-28 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising diquafosol
US11166974B2 (en) 2012-03-26 2021-11-09 Santen Pharmaceutical Co., Ltd. Ophthalmic solution comprising Diquafosol

Similar Documents

Publication Publication Date Title
KR101305649B1 (en) Product containing prostaglandin having fluorine atom in molecule
CY1124690T1 (en) POSACONAZOLE INTRAVENOUS SOLUTION PREPARATIONS STABILIZED WITH BETA-SUBSTITUTED CYCLODEXTRIN
JP2018109005A (en) Formulations of bendamustine
PE20081361A1 (en) PHARMACEUTICAL COMPOSITIONS OF CLONAZEPAM AND METHODS OF USE OF THE SAME
JP6516831B2 (en) Formulation of cyclophosphamide liquid concentrate
JP6099557B2 (en) Injection solution preparation and method for producing the same
SA518391858B1 (en) Formulations of phosphoramidate derivatives of nucleoside drugs
JP6081173B2 (en) Ophthalmic aqueous composition
JP2011516509A (en) Aqueous pharmaceutical formulation
JP2023052927A (en) Aqueous ophthalmic composition
JP2009504634A (en) Aqueous anesthetic composition comprising propofol
BR112012025521A2 (en) liquid injectable composition and use, pharmaceutical composition and use, container and use, method for preparing a composition and use of hydroxyethyl starch
JP2008094839A (en) Ophthalmic agent
AU2013342069B2 (en) Enema composition for treatment of ulcerative colitis having long term stability
JP2021130657A (en) Pharmaceutical product
JP2008247828A (en) Aqueous medicine composition containing latanoprost
JP2016522257A (en) Stable bromfenac solution
JP2005535644A5 (en)
JPH075456B2 (en) Eye drops
JP4754149B2 (en) Aqueous liquid
JP2005330271A (en) Liquid agent for eyedrop
JP4892291B2 (en) Ophthalmic preservative composition
WO2019167979A1 (en) Pharmaceutical composition with excellent storage stability
JP2008120795A (en) Liquid formulation applicable to mucosa
JP2014089482A (en) Contact lens wearing liquid

Legal Events

Date Code Title Description
A621 Written request for application examination

Effective date: 20091109

Free format text: JAPANESE INTERMEDIATE CODE: A621

A977 Report on retrieval

Effective date: 20120517

Free format text: JAPANESE INTERMEDIATE CODE: A971007

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120529

A02 Decision of refusal

Effective date: 20121016

Free format text: JAPANESE INTERMEDIATE CODE: A02